LobbyingKaryopharm Therapeutics lobbying by quarter
Karyopharm Therapeutics KPTI's latest lobbying report covers Q2 2026, at under $5,000. The four quarters Q4 2025–Q3 2026 total $100K. Its first report covers Q4 2025; the issues it reports most are Health Issues.
Karyopharm TherapeuticsKPTI
- Latest quarter
- No record
- Q3 2026 · 0 reports
- Last 12 months
- $100K
- Last 4 quarters
- vs last quarter
- No record
- Q3 2026 against the quarter before
- First report
- Q4 2025
- The first quarter a report named it
Lobbying by quarter
| Quarter | Amount | Reports |
|---|---|---|
| Q4 2025 | $100K | 1 |
| Q1 2026 | $0 | 1 |
| Q2 2026 | $0 | 1 |
| Q3 2026 | $0 | 0 |
By issue
- Health issues$100K · 3 reports
An issue's amount splits each report's amount equally over the issues the report lists.
Who was lobbied
- HOUSE OF REPRESENTATIVES3 reports
- SENATE3 reports
Firms it paid
| Firm | ||
|---|---|---|
| Sidley Austin | $100K | 3 quarters |
Former officials lobbying for it
| Former position | ||
|---|---|---|
| ABIGAIL CARROLL | Detailee to the Energy and Commerce Committee, U.S House of Representatives | Q2 2026 |
| PATRICIA LOUISE DELOATCHE | Health Policy Director, Sen Orrin Hatch; Chief of Staff, Legislative Director, Legislative Assistant, Rep. Mike Bilirakis | Q2 2026 |
Lobbying reports
| Filed by | ||
|---|---|---|
| 07/20for Q2 | Sidley Austin | Under $5,000 |
| 04/20for Q1 | Sidley Austin | Under $5,000 |
| 01/20for Q4 2025 | Sidley Austin | $100K |
| 01/09for Q4 2025 | Sidley Austin | Under $5,000 |
| 01/05for Q4 2025 | Sidley Austin | Under $5,000 |